Moss Adams Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$688K Sell
28,570
-2,658
-9% -$69.5K 0.04% 123
2026
Q1
$877K Buy
31,228
+3,290
+12% +$87.6K 0.06% 96
2025
Q4
$696K Sell
27,938
-180
-0.6% -$4.54K 0.05% 106
2025
Q3
$716K Buy
28,118
+1,167
+4% +$28.8K 0.06% 102
2025
Q2
$653K Sell
26,951
-809
-3% -$18.9K 0.06% 112
2025
Q1
$703K Buy
27,760
+6,234
+29% +$163K 0.07% 85
2024
Q4
$571K Sell
21,526
-585
-3% -$15.9K 0.06% 92
2024
Q3
$640K Buy
22,111
+1,141
+5% +$33.3K 0.07% 81
2024
Q2
$587K Buy
20,970
+5,823
+38% +$160K 0.08% 74
2024
Q1
$420K Buy
15,147
+1,638
+12% +$45.5K 0.07% 85
2023
Q4
$389K Buy
13,509
+2,175
+19% +$65.8K 0.08% 63
2023
Q3
$376K Buy
11,334
+946
+9% +$33.5K 0.13% 52
2023
Q2
$381K Buy
10,388
+206
+2% +$8.02K 0.12% 53
2023
Q1
$415K Sell
10,182
-1,953
-16% -$84.4K 0.14% 51
2022
Q4
$622K Buy
+12,135
New +$582K 0.31% 49

Other funds holding PFE

Moss Adams Wealth Advisors's PFE Position: Q2 2026 in Review

Moss Adams Wealth Advisors reduced its Pfizer (PFE) stake by 8.5% in Q2 2026, selling an estimated $69.5K and leaving 28,570 shares worth $688K. The position accounts for 0.04% of the portfolio, ranked #123.

Moss Adams Wealth Advisors first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $877K in Q1 2026. 1,197 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Moss Adams Wealth Advisors held 28,570 shares of Pfizer worth $688K as of Q2 2026.
  • Moss Adams Wealth Advisors sold 2,658 Pfizer shares in Q2 2026, an estimated $69.5K.
  • Pfizer made up 0.04% of Moss Adams Wealth Advisors's portfolio in Q2 2026, its #123 holding.
  • Moss Adams Wealth Advisors first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • Moss Adams Wealth Advisors's Pfizer position peaked at $877K in Q1 2026.
  • 1,197 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Moss Adams Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.